BLACK WEEKSFlakoni −15% · komplekti −10% · pārējais −5%ar koduBezmaksas piegāde Vācijā no €200

Šī lapa ir tulkota automātiski un var saturēt kļūdas. Vai latviešu valoda ir jūsu dzimtā valoda? Mēs labprāt saņemsim jūsu atsauksmes un labojumus.Sūtīt atsauksmi

The Peptide Desk The Peptide Desk
Retatrutide, produkta foto

7 laboratorijas ziņojumi

PDF
99%
Tīrība
Pārbaudīts
Retatrutide 10mg
Laboratorija
Analiza Białek
Datums
November 2026
Rezultāts
99% purity (10.37 mg measured)
Endotoksīni
5.54 EU/vial
Pasūtījuma nr.
Parole

Neatkarīgi pārbaudīts, ar paroli pārbaudāms tieši laboratorijā.

GLP-1

Retatrutide

GLP-1

Pasūtījums

Vienības cena - Bezmaksas piegāde Vācijā no 200 € Black Weeks laikā
  • DHL ar izsekošanu
  • Diskrēts iepakojums

4.6 no 5 Trustpilot73 atsauksmes

Meklēts arī kā: Retatrutid · Reta · LY3437943

Īsumā

Retatrutide skaitļos

Galvenie rādītāji no mūsu leksikona. Velciet punktu pa līkni, lai redzētu, cik daudz paliek pēc vienas devas, pēc aprēķina.

Pilns leksikona ieraksts

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~6 days

Half-life ~6 days
After 12 days: 25 %
Day 650 %Day 7, next dose45 %Day 1225 %Day 1812.5 %Day 303.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

~6days

Class
Triple agonistGLP-1 / GIP / glucagon
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
5 to 60 mg11 sizes in the shop

Zināšanas

Viss par Retatrutide

Noderēs

Kas jums vēl būs vajadzīgs

Bakteriostatiskais ūdens tiek automātiski pievienots grozam. Šļirces un salvetes - ar vienu klikšķi.

Insulīna šļirces

10 gab. · 5.50 €

Spirta salvetes

50 gab. · 10 €

Cik daudz ūdens?

Vienības uz šļirces jūsu flakona izmēram.

Atvērt kalkulatoru →

FAQ

Bieži uzdotie jautājumi

Avoti katrai atbildei: leksikona ieraksts

Vēl ir jautājums?

Rakstiet mums, mūsu komanda jums palīdzēs.

Is Retatrutide approved?

No, as of 25 October 2026 there is no approval. Retatrutide is in phase 3: 14 phase 3 trials are listed on ClinicalTrials.gov, five of them completed. The first phase 3 results were published in 2026.

How does Retatrutide differ from Tirzepatide and Semaglutide?

The number of receptors. Semaglutide acts only on the GLP-1 receptor, Tirzepatide on GLP-1 and GIP. Retatrutide also targets the glucagon receptor. In animal models this added higher energy expenditure. A head-to-head trial against Tirzepatide is still running (TRIUMPH-5).

What did the phase 3 trials show?

In TRIUMPH-1 (obesity without diabetes) weight fell by 25.0 percent on average after 80 weeks at the highest study dose, by 3.9 percent on placebo. In TRIUMPH-2 (with type 2 diabetes) it was 18.8 versus 5.1 percent. In TRANSCEND-T2D-1 long-term blood sugar (HbA1c) fell by up to 1.94 percentage points in 40 weeks.

What happens to liver fat?

In a substudy with fatty liver (MASLD) liver fat fell by about 81 to 82 percent after 24 weeks in the two higher levels. 86 percent reached normal liver fat below 5 percent at the highest level. A large phase 3 trial on liver disease runs until 2030.

Which side effects were seen?

Most often gastrointestinal effects such as nausea and diarrhoea, depending on the dose. In TRIUMPH-2 abnormal skin sensations (dysaesthesia) and low blood pressure occurred more often than on placebo. In the phase 2 trial heart rate rose in a dose-dependent way, most around week 24.

Which trials are still running?

Nine phase 3 trials are not finished yet. The largest: TRIUMPH-OUTCOMES on heart and kidney events with about 10,000 participants (planned end 2029) and SYNERGY-Outcomes on fatty liver (2030). The comparison with Tirzepatide (TRIUMPH-5) is due to reach its primary endpoint in November 2026.

Salīdzinājumi

Kā tas atšķiras

Saistītie

Saistītie produkti